Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EDP-322 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Intervention | EXPERIMENTAL | EDP-322 v. Placebo |
| Name | Type | Description |
|---|---|---|
| EDP-322 | DRUG | - |
Inclusion Criteria: * Healthy adult males or females between 18 and 45 years of age * Females are eligible if documentation exists that they are surgically sterilized * In good general health \[determined by medical history, physical examination, clinical laboratory tests, and without evidence of a...
EDP-322 is an investigational small molecule being developed for the treatment of skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
The specific molecular target of EDP-322 has not been disclosed in available information. It is being studied for its potential to treat skin and soft tissue infections, including MRSA, but its mechanism of action is not publicly detailed.
EDP-322 is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company publicly traded under the ticker symbol ENTA. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of the drug.
EDP-322 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not received FDA approval for any indication.
EDP-322 has been studied in two completed Phase 1 trials: NCT00989872, a single ascending-dose study in healthy volunteers, and NCT00990145, a multiple ascending-dose study. Both trials were conducted in the United States and enrolled healthy adult participants.